



1644  
JUN 14 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Ronit EISENBERG et al

Serial No.: 10/009,809

Filed: April 26, 2002

Group Art Unit: 1644

For: NOVEL ANTI-ALLERGIC AGENTS

Attorney  
Docket: 30836  
Previously: 24025-501

Examiner: CROWDER, Chun

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

06/21/2006 HAL111 0000052 501407 10009809

01 FC:1806 180.00 DA

Respectfully submitted,

Martin D. Moynihan  
Registration No. 40,338

Dated: June 14, 2006



JUN 19 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p><b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<p><b>Complete if Known</b></p>	
				Application Number	10/009,809
				Filing Date	April 26, 2002
				First Named Inventor	Ronit EISENBERG et al
				Art Unit	1644
				Examiner Name	CROWDER, Chun
Sheet	1	of	2	Attorney Docket Number	30836

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)				
Examiner Signature				Date Considered		

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/009,809
Filing Date	April 26, 2002
First Named Inventor	Ronit EISENBERG et al
Group Art Unit	1644
Examiner Name	CROWDER, Chun

Sheet	2	Of	2	Attorney Docket Number	30836
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	1	Lin et al. "Inhibition of Nuclear Translocation of Transcription Factor NF- $\kappa$ B by A Synthetic Peptide Containing A Cell Membrane-Permeable Motif and Nuclear Localization Sequence", The Journal of Biological Chemistry, 270(24): 14255-14258, 1995.			
	2	Merck Manual "Multiple Sclerosis", The Merck Manual of Dignosis and Therapy, 17th Ed., Sec.14(Chap.180): 1-4, 1999.			
	3	Aridor et al. "Exocytosis in Mast Cells by Basic Secretagogues: Evidence for Direct Activation of GTP-Binding Proteins", Journal of Cell Biology, 111: 909-917, 1990.			
	4	Aridor et al. "Neomycin Is A Potent Secretagogue of Mast Cells That Directly Activates A GTP-Binding Protein Involved in Exocytosis", Journal of Cell Biology, 111: 2885-2891, 1990.			
	5	Columbo et al. "Substance P Activates the Release of Histamine From Human Skin Mast Cells Through A Pertussis Toxin-Sensitive and Protein Kinase C-Dependent Mechanism", Clinical Immunology and Immunopathology, 81(1): 68-73, 1996. Abstract.			
	6	Devilliers et al. "Histamine Release and Local Responses of Rat and Human Skin to Substance P and Other Mammalian Tachykinins", Pharmacology, 32: 340-347, 1986. Abstract.			
	7	Emadi-Khiav et al. "Human and Rat Cutaneous Mast Cells: Involvement of A G Protein in the Response to Peptidergic Stimuli", European Journal of Pharmacology, 272: 97-102, 1995. Abstract.			
	8	Ennis et al. "Some Studies on the Release of Histamine From Mast Cells Stimulated With Polylysine", British Journal of Pharmacology, 70: 329-334, 1980. Abstract.			
	9	Goldberg et al. "Cutaneous Responses to Histamine, Compound 48/80, and Codeine in Patients With Chronic Renal Failure", Annals of Allergy, 67: 525-528, 1991. Abstract.			
	10	Gomperts et al. "Intracellular Mechanisms Regulating Exocytotic Secretion in Mast Cells", International Archives of Allergy and Applied Immunology, 94: 38-46, 1991. Abstract.			
	11	Hawiger "Cellular Import of Functional Peptides to Block Intracellular Signaling", Current Opinion in Immunology, 9(2): 189-194, 1997. Abstract.			
	12	Kivity et al. "The Effect of Food and Exercise on the Skin Response to Compound 48/80 in Patients With Food-Associated Exercise-Induced Urticaria-Angioedema", Journal of Allergy and Clinical Immunology, 81: 1155-1158, 1988. Abstract.			
	13	Mousli et al. "Peptidergic Pathway in Human Skin and Rat Peritoneal Mast Cell Activation", Immunopharmacology, 27(1): 1-11, 1994. Abstract.			
	14	Pearce et al. "Characteristics of Histamine Secretion Induced by Neuropeptides: Implications for the Relevance of Peptide-Mast Cell Interactions in Allergy and Inflammation", International Archives of Allergy and Applied Immunology, 88: 129-131, 1989. Abstract.			
	15	Prochiantz "Getting Hydrophilic Compounds Into Cells: Lessons From Homeopeptides", Current Opinion in Neurobiology, 6: 629-634, 1996. Abstract.			
	16	Sussman et al. "Evaluation of Skin Test Response Using Two Techniques of Measurement", Annals of Allergy, 48: 75-77, 1982. Abstract.			
Signature				Considered	